Obesity problem starts early phase of therapy in children with acute lymphoblastic leukemia

October 26, 2018, St. Jude Children's Research Hospital

Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and researchers at St. Jude Children's Research Hospital have discovered that this problem starts during remission-induction treatment and suggests that early intervention should be considered.

Chemotherapy drugs to treat ALL contribute to myriad problems, one of which is an increased risk of becoming overweight or obese. And because patients are growing, can also affect their height.

Researchers studied 372 children with ALL and reviewed changes in their (BMI), height and weight from diagnosis to five years off therapy. The scientists' findings show that obesity was prevalent—and height growth, especially in patients with identified risk factors (age ≥10 years at diagnosis, standard/high-risk status, white blood cell count ≥ 50×109/L at diagnosis, and positive central nervous system disease)—was compromised.

"Once we found these large increases in BMI over time, we then have to look at intervention," said first author Emily Browne, D.N.P, R.N., C.P.N.P., director of the Transition Oncology Program at St. Jude. "If we could intervene, when should we?"

The answer: As soon as possible.

"Over the whole population that was studied, we found statistically significant even during remission-induction therapy," said corresponding author Hiroto Inaba, M.D., Ph.D., member in the St. Jude Department of Oncology. "We saw a need for an intervention at that point."

To address weight gain, they strongly suggest early interventions. These interventions include parent and guardian education about proper diet and exercise, which encompass cutting down sugar intake and instituting some sort of baseline activity level. For the issue of height, the researchers recommend evaluating certain patients for growth hormone deficiency. The results of this study appeared October 16 in the scientific journal Cancer.

"When you look at the literature of childhood obesity prevention for the general population, there are interventions that could also help ALL patients," Browne said. "But we need to adapt those recommendations to take the cancer therapy into account."

Here's the problem: Medications like glucocorticoids stimulate fat production and appetite. In addition, cancer treatment can cause nausea, pain and fatigue. Therefore, many patients aren't eating healthfully or physically active during therapy. These factors can lead to the increased risk of obesity, which can result in substantial physical and psychosocial morbidity and can possibly complicate infections, high blood pressure, and bone health. Treatment also causes growth issues. Younger children may be able to overcome this issue because they still grow after therapy is completed, but older children may suffer more because they are at a later stage of development which is compromised with therapy.

"We want to create a multidisciplinary approach in working with patients and their parents, including meeting the family where they are and finding when they want to or are ready to make some changes," Inaba said.

Evidence-based obesity-prevention guidelines recommend using motivational interviewing to work with the patient and family to establish goals for behavioral change, such as decreasing sugar-sweetened beverage consumption and decreasing screen time.

Inaba and Browne recommend using a team of oncologists, nurses, dietitians, physical therapists, psychologists and endocrinologists to intervene at the beginning of therapy to establish an appropriate diet and activity level the patient and family can maintain.

Further study is needed to address the height consequences of therapy.

"We are hoping new therapeutic options can decrease intensity of chemotherapy and keep normal tissues intact," Inaba said. "But until then, we're collaborating with multiple clinical departments to help ensure a good, quality cure and a good quality of life in survivorship."

Explore further: Rapid weight gain during infancy possible risk factor for later obesity in kids with autism

More information: Emily K. Browne et al. Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia, Cancer (2018). DOI: 10.1002/cncr.31736

Related Stories

Rapid weight gain during infancy possible risk factor for later obesity in kids with autism

September 6, 2018
Childhood obesity is a serious public health concern that can have a profound impact on children's health and well-being. Children with Autism Spectrum Disorder (ASD) are more likely to have obesity compared to their peers ...

Measuring treatment response proves to be a powerful tool for guiding leukemia treatment

March 20, 2015
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy should help boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. ...

Obese youths with leukemia more likely to have persistent disease

October 27, 2014
Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the ...

Study shows diet and exercise improve treatment outcomes for obese pediatric cancer patients

September 21, 2017
Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson Children's Cancer Hospital.

Certain treatments for childhood cancer may increase obesity risk later in life

May 11, 2015
Childhood cancer survivors - especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids - are 14 percent more likely to be obese than their healthy peers. The St. Jude Children's Research ...

Good news for young patients with a leukemia subtype associated with a poor prognosis

September 24, 2014
St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype ...

Recommended for you

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.